JP4550051B2 - 全身性エリテマトーデスの同定およびモニタリング - Google Patents
全身性エリテマトーデスの同定およびモニタリング Download PDFInfo
- Publication number
- JP4550051B2 JP4550051B2 JP2006513114A JP2006513114A JP4550051B2 JP 4550051 B2 JP4550051 B2 JP 4550051B2 JP 2006513114 A JP2006513114 A JP 2006513114A JP 2006513114 A JP2006513114 A JP 2006513114A JP 4550051 B2 JP4550051 B2 JP 4550051B2
- Authority
- JP
- Japan
- Prior art keywords
- individual
- complement
- bound
- lupus erythematosus
- systemic lupus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 15
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 103
- 238000000034 method Methods 0.000 claims abstract description 58
- 230000000295 complement effect Effects 0.000 claims abstract description 10
- 108010042293 complement C4d Proteins 0.000 claims description 75
- 230000027455 binding Effects 0.000 claims description 22
- 230000009266 disease activity Effects 0.000 claims description 22
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 claims description 19
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 claims description 19
- 238000000684 flow cytometry Methods 0.000 claims description 17
- 238000011002 quantification Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims 7
- 210000001772 blood platelet Anatomy 0.000 description 75
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000037361 pathway Effects 0.000 description 14
- 239000000306 component Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 206010025135 lupus erythematosus Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 102000006834 complement receptors Human genes 0.000 description 3
- 108010047295 complement receptors Proteins 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108010078015 Complement C3b Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 101710137943 Complement control protein C3 Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 101710132637 Protein C2 Proteins 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 101710136899 Replication enhancer protein Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 238000011497 Univariate linear regression Methods 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Small-Scale Networks (AREA)
- Testing Of Coins (AREA)
- Dc Digital Transmission (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46344703P | 2003-04-16 | 2003-04-16 | |
| PCT/US2004/011982 WO2004093647A2 (en) | 2003-04-16 | 2004-04-16 | Identification and monitoring of systematic lupus erythematosus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524342A JP2006524342A (ja) | 2006-10-26 |
| JP2006524342A5 JP2006524342A5 (cg-RX-API-DMAC7.html) | 2007-06-07 |
| JP4550051B2 true JP4550051B2 (ja) | 2010-09-22 |
Family
ID=33310779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513114A Expired - Lifetime JP4550051B2 (ja) | 2003-04-16 | 2004-04-16 | 全身性エリテマトーデスの同定およびモニタリング |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7588905B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1618379B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4550051B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE552501T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004232007B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2522261A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004093647A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060015646A (ko) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| US20080131914A1 (en) * | 2005-09-14 | 2008-06-05 | Ahearn Joseph M | Assessing risk of cerebrovascular thrombosis by measuring c4d |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| WO2010045611A2 (en) * | 2008-10-16 | 2010-04-22 | Cypress Bioscience, Inc. | Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases |
| JP5625155B2 (ja) * | 2010-07-30 | 2014-11-19 | 国立大学法人 東京大学 | ホスファチジルセリン特異的ホスホリパーゼａ１測定による全身性エリテマトーデスの検査方法および検査薬 |
| EP2673644B1 (en) | 2011-02-11 | 2016-02-10 | Exagen Diagnostics, Inc. | Methods for diagnosing systemic lupus erythematosus |
| US9863946B2 (en) | 2013-02-08 | 2018-01-09 | Allegheny-Singer Research Institute | Cell-bound complement activation products as diagnostic biomarkers for pre-lupus |
| EP2954071B1 (en) | 2013-02-08 | 2020-08-12 | Allegheny-Singer Research Institute | Cell-bound complement activation products as diagnostic biomarkers for pre-lupus |
| US11531033B2 (en) | 2013-03-15 | 2022-12-20 | Exagen Inc. | Methods for treating and diagnosing systemic lupus erythematosus |
| US10105413B2 (en) | 2013-06-13 | 2018-10-23 | Medical Research & Development Fund for Health Services Bnai Zion Medical Center | Semaphorin 3A for treatment of systemic lupus erythematosus |
| JP6674543B2 (ja) | 2015-07-31 | 2020-04-01 | アレゲーニー・シンガー リサーチ インスティチュート | 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ |
| WO2017205532A1 (en) | 2016-05-24 | 2017-11-30 | Allegheny-Singer Research Institute | Methods and systems using c4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU686577B2 (en) | 1992-10-30 | 1998-02-12 | Innogenetics, Inc. | Measurement of total molecule in a sample and methods based thereon |
| EP1066368A4 (en) * | 1998-03-02 | 2002-08-21 | Compucyte Corp | SELECTIVE CELL ANALYSIS |
| JP4570872B2 (ja) * | 2001-09-10 | 2010-10-27 | ユニヴァーシティ オブ ピッツバーグ | 全身性紅斑性狼瘡および強皮症の診断およびモニタリング方法 |
| KR20060015646A (ko) * | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| EP1756571B8 (en) * | 2004-04-09 | 2010-10-13 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Real time method of detecting acute inflammatory conditions |
| ES2353311T3 (es) * | 2004-05-11 | 2011-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Diagnóstico de enfermedades o afecciones inflamatorias para la medición de componentes del complemento sobre la superficie de glóbulos blancos. |
| US7679298B2 (en) * | 2006-08-17 | 2010-03-16 | General Electric Company | Locomotive wheel speed control |
-
2004
- 2004-04-16 CA CA002522261A patent/CA2522261A1/en not_active Abandoned
- 2004-04-16 WO PCT/US2004/011982 patent/WO2004093647A2/en not_active Ceased
- 2004-04-16 JP JP2006513114A patent/JP4550051B2/ja not_active Expired - Lifetime
- 2004-04-16 AU AU2004232007A patent/AU2004232007B2/en not_active Ceased
- 2004-04-16 AT AT04759986T patent/ATE552501T1/de active
- 2004-04-16 US US10/552,177 patent/US7588905B2/en not_active Expired - Lifetime
- 2004-04-16 EP EP04759986A patent/EP1618379B1/en not_active Expired - Lifetime
-
2009
- 2009-08-07 US US12/538,001 patent/US8126654B2/en not_active Expired - Lifetime
-
2012
- 2012-01-25 US US13/358,428 patent/US20120122241A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1618379A2 (en) | 2006-01-25 |
| WO2004093647A3 (en) | 2005-03-10 |
| ATE552501T1 (de) | 2012-04-15 |
| CA2522261A1 (en) | 2004-11-04 |
| JP2006524342A (ja) | 2006-10-26 |
| US7588905B2 (en) | 2009-09-15 |
| WO2004093647A2 (en) | 2004-11-04 |
| US20070178536A1 (en) | 2007-08-02 |
| EP1618379A4 (en) | 2008-05-07 |
| US8126654B2 (en) | 2012-02-28 |
| AU2004232007B2 (en) | 2009-10-22 |
| AU2004232007A1 (en) | 2004-11-04 |
| EP1618379B1 (en) | 2012-04-04 |
| US20090299948A1 (en) | 2009-12-03 |
| US20120122241A1 (en) | 2012-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8126654B2 (en) | Identification and monitoring of systemic lupus erythematosus | |
| JP4906898B2 (ja) | 全身性紅斑性狼瘡および強皮症の診断およびモニタリング方法 | |
| US11761965B2 (en) | Methods for diagnosing systemic lupus erythematosus | |
| CA2564492C (en) | Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells | |
| AU2002323691A1 (en) | Diagnosis and monitoring of systemic lupus erythematosus and of scleroderma | |
| US6140065A (en) | Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm | |
| Abraham et al. | Performances of ICT Toxoplasma IgG-IgM test in comparison with Vidas® toxo competition to determine the immune status against Toxoplasma gondii | |
| Waldherr et al. | Basophil activation in insect venom allergy: comparison of an established test using liquid reagents with a test using 5-color tubes with dried antibody reagents | |
| Thomas et al. | Analytical and clinical performance of improved Abbott IMx CA 125 assay: comparison with Abbott CA 125 RIA | |
| Mahir et al. | Performance evaluation of immunoblot for the detection of anti-DNA antibodies compared to indirect immunofluorescence on Crithidia luciliae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070330 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100402 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100616 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100707 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4550051 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130716 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |